Anterior chamber lenses in the management of subluxated lenses

Article

Anterior chamber lenses in the management of subluxated lenses

Ophthalmology needs a large-scale, probably multicentre prospective trial to fully understand and codify the management of subluxated lenses, according to Dr Gunther Grabner, addressing delegates meeting in Barcelona.

“We need the data to create a decision tree to help surgeons find the best option for these cases among those available,” he said. Doctors need better data to help them decide between surgical options.

Dr. Grabner said that subluxated lenses are an uncommon condition. A study of cases at his clinic showed that it was less than 0.94% per year, which is comparable to similar clinics. “It is 1 out of every 226 cataract surgery cases, so we can say it's a fairly uncommon event.”

He said the surgical options in these cases included anterior chamber lenses (ACL) as the angle supported and iris claw, and posterior chamber lens (PCL) options included the sclera fixated, iris sutured or posteriorly enclavated iris claw lens.

Angle supported lenses were reported to have performed very well and were indicated in the presence of bleeding disorders, extensive sclerocorneal scarrin, an intact anterior vitreous face and when surgery had to be quick, as with older patients.

However, they should not be used where there were corneal endothelial problems or shallow chamber, abnormal angle, or where there was glaucoma and iris-defects, such as aniridia. “I don't think they should be used in patients with a life expectancy of more than 10 years,” he said.

Outlining the advantage of ACLs over PCLs , he said ACLs offer short surgical time, less bleeding, easy insertion and removal with minimal or no vitrectomy required. “And there are no problems of haptic placement, lens tilt and dislocation,” he noted.

Other advantages included no suture problems, minimal uveal contact and long term proven biocompatibility. PCLs, on the other, held the advantage in eyes with angle problems or endothelial damage, and PCLs are not dependent on the condition of the iris.

Dr. Grabner wound up his talk by demonstrating his surgery technique for posteriorally enclavated iris claw lens, which he said he liked a lot. However, he concluded by saying: “I think we have very few comparative, long-term studies comparing anterior chamber lenses and the other options. I think we have a need for a long term study.”

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.